On Monday, an industry analyst highlighted several key developments in the medical device sector, noting increased investor interest ahead of Edwards Lifesciences' (NYSE:EW) Investor Day. The analyst pointed out that the primary focus of investor inquiries was on the company's outlook for 2025, a topic previously emphasized in weekly updates.
The analyst also provided insights into the competitive landscape of leadless pacemakers, drawing attention to Abbott Laboratories ' (NYSE:NYSE:ABT) Aveir dual-chamber leadless pacemaker. This device is positioned as a competitor to Medtronic PLC (BVMF:MDTC34)'s (NYSE:MDT) Micra.
The discussion extended to the field of atrial fibrillation (Afib) treatments, comparing Boston Scientific Corporation's (NYSE:NYSE:BSX) Farapulse to Medtronic (NYSE:MDT)'s Affera. Boston Scientific, currently trading near its 52-week high, has demonstrated impressive momentum with a 61.5% return over the past year. According to InvestingPro data, 20 analysts have recently revised their earnings estimates upward for the upcoming period.
In the diabetes care segment, the analyst remarked on Abbott's strategic positioning, which could influence its market share. Moreover, the analyst shared observations on the sustained interest in GLP-1 adoption, a class of drugs used in diabetes management, indicating ongoing market dynamics in this therapeutic area.
The insights were derived from the latest buy-side checks, which involve analysts gathering information from investors who buy securities for their own accounts. These checks serve as a pulse on market sentiment and potential shifts in competitive advantages among leading companies in the medical device industry.
In other recent news, Boston Scientific has completed its acquisition of Axonics, a strategic move aimed at bolstering its Urology and Pelvic Health business. This acquisition is expected to have a neutral impact on the company's adjusted earnings per share (EPS) for 2024 and 2025, with positive contributions anticipated in subsequent years. Revenue estimates for Boston Scientific have been revised upward for 2024 and 2025 following this acquisition.
Boston Scientific has also announced a definitive agreement to acquire Intera Oncology Inc., a specialist in liver cancer treatment devices and medication, expected to conclude in the first half of 2025. This acquisition aims to enhance Boston Scientific's interventional oncology portfolio.
The company's stock maintains its Hold rating by a prominent financial firm. In addition, Boston Scientific has approved its 2025 Annual Bonus Plan and adopted two new performance share programs.
Boston Scientific has resumed its AVANT GUARD clinical trial, focusing on a new treatment option for patients with persistent atrial fibrillation. The company also plans to acquire Cortex, a private firm with a unique cardiac mapping system, a move positively received by analysts at TD Cowen.
These are recent developments that reflect Boston Scientific's commitment to innovation and growth, particularly in the cardiology market. The company reported robust growth rates in its cardiology business, with a 27% increase in the U.S. and 18% internationally. The company is also investing in mitral and tricuspid therapies, aiming to double the global drug-coated balloon business by 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.